胸水稀释联合尿激酶胸腔注入治疗结核性胸膜炎38例临床观察  

CLINICAL OBSERVATION OF 38 CASES OF TUBERCULOUS PLEURISY WITH HYDROTHORAX DILUTION COMBINED UROKINASE INJECTION INTO THE THORACIC CAVITY TREATMENT

作　　者：石贵江[1] 杨峰[1] 黄修平[1] 邱承毅 满益伍 许官学[1] 

机构地区：[1]贵州省石阡县人民医院内科,贵州555100

出　　处：《现代预防医学》2011年第13期2642-2643,共2页Modern Preventive Medicine

摘　　要：[目的]观察胸水稀释联合尿激酶胸腔注入对结核性胸膜炎的治疗效果,缩短胸水吸收时间及减少胸膜增厚后遗症。[方法]随机抽样分为胸水稀释联合尿激酶胸腔注入治疗组和对照组,在全身化疗的基础上,用0.9氯化钠作为胸水稀释液,联合尿激酶胸腔注入。[结果]两组对比之间的差异有统计学意义(P﹤0.05),胸水吸收治愈率,治疗组81.6,对照组50;胸水10d以内吸收者,治疗组50,对照组14.7;胸膜增厚,治疗组16,对照组44.1。[结论]胸水稀释联合尿激酶胸膜腔注入治疗结核性渗出性胸膜炎有较大临床应用价值。[Objective]To observe the effects of hydrothorax dilution combined with urokinase injection into the thoracic cavity as the treatment for tuberculous pleurisy,to shorten the absorption time of hydrothorax and reduce occurrence of pleura thickening.[Methods]The patients with tuberculous pleurisy were divided into combined-treatment group and control group randomly.Both groups were treated with the systematic chemotherapy,while the combined-treatment group was injected with the 0.9% NaCl to dilute the hydrothorax and urokinase into the thoracic cavity on the basis of chemotherapy.[Results]The cure rate of the hydrothorax absorption was 81.6% in the combined-treatment group,compared with that of 50% in the control group with statistical significance（P﹤0.05）.The hydrothorax was absorbed within 10 days in 50% of patients in the combined-group,while in only 14.7% of patients in the control group.The 16% of patients in the combined-treatment group developed thickened pleural compared with 44.1% of patients in the control group.[Conclusion]The method of hydrothorax dilution combined with urokinase injection into thorax possesses a potential application in the clinical treatment of tuberculous pleurisy.

关 键 词：结核性胸膜炎 胸水稀释 尿激酶 胸膜腔注入 

分 类 号：R521.7[医药卫生—内科学]